Boston Scientific Reports Favorable Six-Month Results From Lotus Valve System Clinical Trial

Boston Scientific Corporation

reported favorable six-month results from the first 60 patients enrolled in the REPRISE II clinical trial evaluating the safety and performance of the Lotus™ Valve System in symptomatic patients with severe aortic stenosis considered at high risk for surgical valve replacement.   The data, which were presented today at PCR London Valves and formally received the honor of Best Abstract 2013, demonstrated excellent results with no new valve-related adverse events between 30 days and six months. Additionally, there were no cases of moderate or severe paravalvular regurgitation in any patient at six months. Six-month results: Excellent hemodynamic results continue to be observed at six months as demonstrated by mean aortic valve pressure gradient of 12.1 ± 5.0 mmHg and mean aortic valve area of 1.8 ± 0.5 cm2. Independent core lab assessment of paravalvular aortic regurgitation showed 76.1 percent of patients presenting with no paravalvular regurgitation and no cases of moderate or severe regurgitation. There were no new valve-related adverse events recorded between 30 days and six months. The NYHA classification data demonstrated a significant improvement in heart failure symptoms at six months